Now is the time to buy, not sell. How many other companies have the current revenue growth of ASTI? They can raise the cash for another year of operating expenses through yet another offering. They could realistically acheive profitability by Q4 2015. The product line is in an infancy of what it could be. And they are only scratching the surface of retailers right now. CEO seems competent but lacking mojo. $10M/quarter revenue is easily attainable, with much more being possible. $10M quarterly and profitability overall would make the stock $5-10.
Yet ASTI stock is totally hated right now. It's a fear fest for small investors and institutions have stayed away.
I wouldn't go so far as saying it's typical. But there's a good chance it will happen.
If smart money finds out early that the results are good...they want to whack it and cover their shorts, or maybe go long.
I think the results will be perceived as good. It now appears that 3422 is nearly a copy of sovaldi, so I would expect it is effective. But the real issue here is patent protection
Interesting that he would take back his initial impression.
One possiblity is that a hedge fund called him up and said "take back that first impression and we'll give you $100k.
Don't listen to others. Think for yourself.
I think ACHN has more worries over Idenix (now owned by Merck) challenging its compound rather than Gilead.
"if it's 4 log with 100% RVR the stock pops regardless"
It's looking like the odds of that happening are very good. So, you think the market will give you that opportunity so easily? Maybe.
Than again, maybe not! (and that goes back to the bear raid scenario)
What company is going to risk buying ACHN for a big premium when there are patent uncertainties. Lawyers can voice their opinions, but remember, these issues ultimately get settled in a court of law.
I could be wrong, but it looks to me like ACHN is infringing, more broadly, upon patents held by IDIX.
Idenix seems to think it has broad claims that cover nucleosides more generally. They felt strongly enough to sue Gilead.
Since the patent app came out a week ago, and it reveals improved potency, why hasn't big pharma scooped them up? Remember...bidding war for IDIX.
Are they waiting for the retail crowd to bid it up to $15, so they can then pay more for it?
He's thinking in terms of the specific chemistry of the compounds. Sure, that's important.
But I think the issue goes back to Idenix vs. Gilead
Idenix says they own THE PROCESS of using uridine nucleosides in HCV treatment.
Merck will keep fighting Gilead on this. And ACHN, who came later in the game, has poorer odds against Merck.
Furthermore, "the trial" results won't provide an adequate safety profile. With increased potency comes risk of toxicity.
clever...I take this to mean that you're the same guy as magnam_pi.
So you didn't really ignore me, did you?
Insinuating that someone is paying for the short articles is a large claim.
On the other hand, Organovo paid Zacks to promote, then the other platform they've been using, and Murphy pumping on twitter...yadayadayada...you'll see how it ends! Hint: it won't be fun for longs!
No new developments...just the CEO appearing on CNBC. Wow, what perfect timing to save the stock! Lol !!!!!!!!!
...said they have "beta" customers...LOL !!!!
...upfront cost is higher ... "potential" savings later ... keyword is potential
said they would have predicted liver tocitiy ..... nooooooo .... this reasoning is in error
drugs are not splashed directly onto our livers....they are for the most part ingested...pass through GI tract, into bloodstream...etc........there's a difference and so liver tissue cannot replace animal testing
So....momo traders have fun. Just remember this is 1,000+ x earnings!!!!
the stock was nearing a colapse....then like magic Murph was on CNBC to save it. I'm beginning to wonder if Cramer and murph are buddies?
and no, not HFT...just regular joes taking their tax losses. There's no disputing the fact that nearly all the longs are now underwater. Only ones with a profit right now had to buy on just a couple of days, yesterday being one of them.
Even as a "spec", as he calls it. It just doesn't fit Cramers style.
Now we have some stronger evidence that Cramer and Murph are buddies and CNBC is in on the manipulation. They probably had this interview pre-recorded and then saved it for the perfect time to force a bit of a squeeze.